Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Ramos-Goñi, J. M.; Axentiva Solutions, Calle el Calvario, Tacoronte, Santa Cruz de Tenerife 38107, Spain
Cuervo, J.; Axentiva Solutions, Calle el Calvario, Tacoronte, Santa Cruz de Tenerife 38107, Spain
Kopylov, U.; Sheba Medical Center, Ramat Gan, Israel, Sackler Medical School, Tel Aviv University, Tel Aviv, Israel
Acosta, M. B.-D.; Complejo Universitario de Santiago de Compostela, Santiago de Compostela, Spain
McCartney, S.; University College London Hospitals, London, United Kingdom
Rosenfeld, G.; University of British Columbia, 770-1190 Hornby St., Vancouver, BC V3K 3V9, Canada
Bettenworth, D.; Department of Medicine B, Gastroenterology and Hepatologie, University Hospital Munster, Albert-Schweitzer-Campus 1, Münster, 48149, Germany
Hart, A.; London North West Healthcare, London, United Kingdom
Novak, K.; The University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N4N1C, Canada
Donnet, X.; Association Crohn-RCUH, 2 Rue des Argentines, Montigny-le-Tilleul, 6110, Belgium
Easton, D.; Canada Crohn’s and Colitis, Canada, 220 Stiver St., Russell, ON K4R 1G9, Canada
Saldaña, R.; Confederación de Asociaciones de Enfermos de Crohn y Colitis Ulcerosa de España, Madrid, Spain
Cosnes J, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785–94.
Kumar V, Abbas AK, Fousto N, Robbins SL, Cotran RS. Robbins and Cotran pathologic basis of disease. 9th ed. Philadelphia, PA: Saunders Elsevier; 2015.
Ng SC, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769–78.
Conway G, et al. The impact of co-existing immune-mediated diseases on phenotype and outcomes in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;45(6):814–23.
Singh S, et al. Variations in the medical treatment of inflammatory bowel disease among gastroenterologists. Gastroenterol Rep (Oxf). 2018;6(1):61–4.
Kariburyo MF, et al. Predicting pre-emptive discussions of biologic treatment: results from an openness and preference survey of inflammatory bowel disease patients and their prescribers. Adv Ther. 2017;34(6):1398–410.
Stevens K, Palfreyman S. The use of qualitative methods in developing the descriptive systems of preference-based measures of health-related quality of life for use in economic evaluation. Value Health. 2012;15(8):991–8.
Soekhai V, et al. Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. Drug Discov Today. 2019;24(7):1324–31.
Brazier JE, et al. Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome). Health Technol Assess. 2012;16(32):1–114.
US FDA. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims.2009 http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf. Accessed 1 May 2019.
Patrick DL, et al. Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1–eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967–77.
Almario CV, et al. Optimizing selection of biologics in inflammatory bowel disease: development of an online patient decision aid using conjoint analysis. Am J Gastroenterol. 2018;113(1):58–71.
Bewtra M, et al. Patient preferences for surgical versus medical therapy for ulcerative colitis. Inflamm Bowel Dis. 2014;20(1):103–14.
Casellas F, et al. Patient preferences for inflammatory bowel disease treatment objectives. Dig Liver Dis. 2017;49(2):152–6.
van Deen WK, N.D., Duran NE, Kane E, van Oijen MG, Hommes DW. Value redefined for inflammatory bowel disease patients: a choice-based conjoint analysis of patients’ preferences. Quality of Life Research, 2017. 26(2): 455-465.
Kamp KJ, Brittain K. Factors that influence treatment and non-treatment decision making among individuals with inflammatory bowel disease: an integrative review. The Patient - Patient-Centered Outcomes Research. 2018;11(3):271–84.
Trapero-Bertran M, Rodriguez-Martin B, Lopez-Bastida J. What attributes should be included in a discrete choice experiment related to health technologies? A systematic literature review. PLoS ONE. 2019;14(7):e0219905.
Cote-Daigneault, J., et al., Herpes zoster incidence in inflammatory bowel disease patients: a population-based study. Inflamm Bowel Dis, 2018.
Huang SZ, et al. Risk of skin cancers in thiopurines-treated and thiopurines-untreated patients with inflammatory bowel disease: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2019;34(3):507–16.
Ghosh S, et al. Development of the IBD Disk: a visual self-administered tool for assessing disability in inflammatory bowel diseases. Inflamm Bowel Dis. 2017;23(3):333–40.
Cooke A, Smith D, Booth A. Beyond PICO: the SPIDER tool for qualitative evidence synthesis. Qual Health Res. 2012;22(10):1435–43.
Smithson J. Using and analysing focus groups: limitations and possibilities. Int J Soc Res Methodol. 2000;3(2):103–19.
National Health Council. FDA standard core clinical outcome assessments and endpoints (Notice No. NOT-FD-18-014). 2018. http://www.nationalhealthcouncil.org/sites/default/files/NHC%20Core%20Clinical%20Outcome%20Assessments%20Endpoints.pdf. Accessed 3 June 2019.